Currently, Relay Therapeutics Inc [RLAY] is trading at $6.5, down -4.13%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RLAY shares have gain 18.61% over the last week, with a monthly amount glided 57.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Equal Weight rating on April 17, 2025, and set its price target to $4. On September 10, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $16 on the stock. Oppenheimer downgraded its rating to a Perform. Barclays upgraded its rating to Overweight for this stock on May 10, 2024, but kept the price target unchanged to $15. In a note dated April 20, 2023, Jefferies upgraded a Hold rating on this stock but restated the target price of $12.50.
This stock has fluctuated between a low of $1.77 and a high of $7.07 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $19.4 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $6.5 at the most recent close of the market. An investor can expect a potential return of 198.46% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
Gross Profit Margin for this corporation currently stands at -0.15% with Operating Profit Margin at -41.06%, Pretax Profit Margin comes in at -37.28%, and Net Profit Margin reading is -37.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.41 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Relay Therapeutics Inc [NASDAQ:RLAY] is 20.92. Further, the Quick Ratio stands at 20.92, while the Cash Ratio is 3.5. Considering the valuation of this stock, the price to sales ratio is 134.05, the price to book ratio is 1.68.
Transactions by insiders
Recent insider trading involved Rahmer Peter, that happened on Jul 29 ’25 when 15724.0 shares were sold. Rahmer Peter completed a deal on Jul 28 ’25 to sell 1359.0 shares. Meanwhile, Chief Financial Officer Catinazzo Thomas sold 18380.0 shares on Jul 29 ’25.
